Annual report [Section 13 and 15(d), not S-K Item 405]

Revenue - Collaboration Agreement - The GSK Termination and Transfer Agreement (Details)

v3.25.1
Revenue - Collaboration Agreement - The GSK Termination and Transfer Agreement (Details)
 1 Months Ended
Aug. 31, 2024
GBP (£)
Jun. 30, 2024
GBP (£)
Dec. 31, 2023
GBP (£)
Sep. 30, 2023
GBP (£)
Jun. 30, 2023
GBP (£)
Dec. 31, 2024
USD ($)
Apr. 06, 2023
USD ($)
Apr. 06, 2023
GBP (£)
Dec. 19, 2022
USD ($)
Dec. 19, 2022
GBP (£)
GSK Termination and Transfer Agreement                    
Revenue                    
Aggregate amount of the transaction price that is allocated to performance obligations           $ 24,906,000        
Upfront payment received | £         £ 7,500,000          
Milestone payment | £ £ 1,500,000 £ 6,000,000 £ 12,000,000 £ 3,000,000            
Amount of transaction price of the agreement at inception             $ 37,335,000      
Upfront and milestone payment receivable | £               £ 30,000,000    
IGNYTE                    
Revenue                    
Aggregate amount of the transaction price that is allocated to performance obligations           9,837,000        
LTFU                    
Revenue                    
Aggregate amount of the transaction price that is allocated to performance obligations           15,069,000        
GSK Collaboration And License Agreement                    
Revenue                    
Payment by GSK due to termination of collaboration | £                   £ 5,000,000
Aggregate remaining transaction price that had not yet been recognized as revenue                 $ 6,500,000  
Aggregate amount of the transaction price that is allocated to performance obligations           $ 0